Related Experiment Video
Updated: Dec 16, 2025

10:18
Author Spotlight: Exploring Seaweed's Bioactive Compounds for Sustainable Innovations in Industries
Published on: November 21, 2023
3.3K
Re-evaluation of guar gum (E 412) as a food additive
EFSA Journal. European Food Safety Authority
|July 7, 2020
Summary
Guar gum (E 412) is safe for the general population as a food additive, with no numerical acceptable daily intake (ADI) needed. However, its safety for infants and young children requires further investigation.
Area of Science:
- Food Science
- Toxicology
- Regulatory Science
Background:
- Guar gum (E 412) previously received an 'acceptable daily intake' (ADI) not specified by JECFA and SCF.
- Re-evaluation of guar gum safety is mandated by Commission Regulation (EU) No 257/2010.
- Previous evaluations established an ADI 'not specified' for guar gum.
Purpose of the Study:
- To re-evaluate the safety of guar gum (E 412) as a food additive.
- To determine if a numerical ADI is necessary for guar gum.
- To assess the safety of guar gum for specific population groups, including infants and young children.
Main Methods:
- Review of available exposure and toxicity data for guar gum.
- Analysis of subchronic, carcinogenicity, and genotoxicity studies.
- Assessment of oral intake tolerance in adults.
Main Results:
- Guar gum is largely undigested and fermented by gut bacteria, with no adverse effects in toxicity studies.
- Oral intake of guar gum is well tolerated in adults.
- No safety concerns identified for the general population at refined exposure levels.
Conclusions:
- A numerical ADI for guar gum (E 412) is not required; it is safe for the general population.
- Further research is needed to assess guar gum safety in foods for infants and young children, particularly regarding potential abdominal discomfort.
- Safety cannot be adequately assessed for specific infant food categories due to data limitations.
Related Concept Videos
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
89
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
89
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
122
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
122

